News

The Procter & Gamble company is voluntarily recalling three lots of its Vicks Sinex nasal spray in three countries, the US, Germany and the UK. The company said

“Heart failure is one of the most costly medical conditions in the world, with 37% of US Medicare dollars alone spent on heart conditions each year,” said Michael

Quark Pharmaceuticals has reported that four of its siRNA R&D platform based programs have met clinical development milestones. Patient enrollment was completed in three clinical studies and a

NicOx has received a filing communication from the FDA stating that the New Drug Application (NDA) for Naproxcinod is accepted for filing. NicOx submitted the NDA on September

Dow has published a new Company Databook: The Elements of Success. This inaugural edition provides comprehensive insight into Dow as a specialty chemicals and advanced materials company. Andrew

InterMune has modified the on-going Phase 2b study conducted by Roche of ITMN-191 (RG7227) combined with standard of care (SOC) Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) in HCV

UK-based Reaxa has received research and development grant from the Northwest Regional Development Agency (NWDA). The fund for R&D amounts to £146K (E164K). The grant is expected to

MMR Information Systems (MMR) and Unis-Tonghe Technology (Zhengzhou) (UNIS) will enter into a definitive agreement by the end of this year to form a joint venture. The joint

BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its Imvamune smallpox vaccine with